Compare

Adamax vs SLU-PP-332

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Adamax

2198 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 62% · Mixed 28% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
125
Energy
93
Mood
112
Focus
182
Sleep quality
123

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
41
Dizziness
173
Fatigue
77
Nausea
177
Water retention
122

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
16
0.4–0.6 mg
19
0.6–1 mg
10
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing42stacking20side effects28adamax6

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 36% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 484 repeat reporters

SLU-PP-332

134 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 68% · Mixed 22% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-43
Lean mass
-153
Joint comfort
-32
Recovery
-61
Digestive comfort
-65

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-127
Appetite loss
-73
Injection site reaction
-67
Anxiety
-66
Flushing
-66

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–2 mg

0.05–0.1 mg
3
0.1–0.2 mg
5
0.2–0.4 mg
10
0.4–0.6 mg
16
0.6–1 mg
13
1–2 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing18stacking26side effects34slu-pp-33217

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 36% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 16 days · Based on 29 repeat reporters

Sources (5)

Published sources linked on the Adamax and SLU-PP-332 wiki pages.

  1. PubMed

    Semax and its derivatives: neuroprotective peptides (review)

    Ashmarin IP, Nezavibatko VN. Neurosci Behav Physiol. 2018

    Source
    Wiki study page →
  2. PubMed

    Semax, an analog of ACTH(4-7), regulates expression of immune response genes

    Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Mol Genet Genomics. 2013

    Source
    Wiki study page →
  3. PubMed

    An exercise-inducible metabolite that increases endurance via the ERRγ pathway

    Li Z, Wu Y, Wang C, et al. Nat Commun. 2023

    Source
    Wiki study page →
  4. PubMed

    A Synthetic ERR Agonist Alleviates Metabolic Syndrome

    Billon C, Schoepke E, Avdagic A, et al. The Journal of pharmacology and experimental therapeutics. 2024

    Source
    Wiki study page →
  5. PubMed

    Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling

    Okda HE, Zhao P, Hayes M, et al. International journal of biological macromolecules. 2026

    Source
    Wiki study page →